High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors

Authors:

Abstract
No abstract available

This publication has 31 references indexed in Scilit: